Navigation Links
PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients
Date:8/18/2011

SEATTLE For the first time, researchers at Seattle Cancer Care Alliance have demonstrated the feasibility of using serial positron emission tomography (PET) scans, using a special estrogen-containing isotope, to confirm the relative effectiveness of estrogen-blocking and estrogen-depleting therapy in patients with metastatic breast cancer. The results of the research are published online in Clinical Cancer Research.

The PET scans, taken before, during and after hormonal therapy, confirmed the superior effectiveness of estrogen-receptor-blocking drugs such as tamoxifen and fulvestrant over estrogen-depleting therapies such as aromatase inhibitors in blocking the estrogen receptor in cancer cells. The study also confirmed that tamoxifen is superior to fulvestrant in blocking estrogen.

While the results were expected they had never before been proven, according to corresponding author Hannah Linden, M.D., a breast oncologist at SCCA and an associate professor of Medicine at the University of Washington School of Medicine.

Linden and colleagues measured regional estrogen-receptor blocking and binding by using PET scans with 18F-flouroestradiol (FES), a trace amount of estrogen in isotope form, prior to and during treatment with aromatase inhibitors, tamoxifen and fulvestrant in a series of 30 patients whose breast cancer had spread to the bones. Tumor FES uptake declined more markedly in patients who took estrogen-receptor blockers compared to those who took estrogen-depleting aromatase inhibitors (an average decline of 54 percent versus 15 percent, respectively). Among the two estrogen-blocking drugs studied, the rate of complete tumor blockade was highest following use of tamoxifen versus fulvestrant.

"What we're suggesting in the paper -- that we couldn't fully test for before -- is if estrogen is incompletely blocked you're not getting a good outcome for the patient," Linden said.

"Our findings support the ability of FES PET to visualize the in vivo activity of endocrine therapy," the authors concluded. "This technology could be used early in drug development to measure effectiveness at the intended therapeutic targets, and to help refine selection and dosing for agents to move forward in drug development."

Additionally, pharmacodynamic imaging could provide clinicians with a promising tool for therapeutic selection and for predicting and evaluating response to estrogen-receptor-targeted therapy, Linden said.


'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. Use of CT scans in emergency rooms increased 330 percent in 12 years
2. CT scans unleash a breakthrough in catching early stage lung cancer
3. More Evidence CT Scans Better at Detecting Lung Cancer
4. Lung cancer screening trial shows screening with CT scans reduces lung cancer deaths
5. Hospitalizing children with normal CT scans after blunt head trauma is not necessary
6. Brain Scans to Spot Alzheimers May Be Available This Year
7. Chronic Pot Smoking Affects Brain Chemistry, Scans Show
8. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
9. CT Heart Scans No Benefit to Patients Without Symptoms
10. Scans of Egyptian Mummies Show Heart Disease Was Ancient Malady
11. Large study finds CT scans are frequently unnecessary after head injury in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CHAPEL HILL, N.C. , June 24, 2016 ... in healthcare decisions and regulators/payers have placed more ... this new environment, patient support programs in the ... support for patients, medications. Consequently, pharmaceutical companies are ... to ensure they are providing products and services ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology: